Erratum: Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder—An Animal Model and a Human Study

Frontiers Production Office,

doi:10.3389/fnbeh.2022.952004

ERRATUM article

Front. Behav. Neurosci., 10 June 2022

Sec. Emotion Regulation and Processing

Volume 16 - 2022 | https://doi.org/10.3389/fnbeh.2022.952004

Erratum: Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder—An Animal Model and a Human Study

This article is an erratum on:

Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder—An Animal Model and a Human Study
1. Read original article

Frontiers Production Office^*

Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder—An Animal Model and a Human Study

by Bareli, T., Ahdoot, H. L., Ben Moshe, H., Barnea, R., Warhaftig, G., Gispan, I., Maayan, R., Rosca, P., Weizman, A., and Yadid, G. (2021). Front. Behav. Neurosci. 15:788708. doi: 10.3389/fnbeh.2021.788708

Due to a production error, an author name was incorrectly spelled as Hilla Ben Moshe. The correct spelling is Hila Ben Moshe.

The publisher apologizes for this mistake. The original version of this article has been updated.

Keywords: stress, substance-induced depressive disorder, addiction, treatment, therapeutic center, baclofen, opipramol

Citation: Frontiers Production Office (2022) Erratum: Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder—An Animal Model and a Human Study. Front. Behav. Neurosci. 16:952004. doi: 10.3389/fnbeh.2022.952004

Received: 24 May 2022; Accepted: 24 May 2022;
Published: 10 June 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Erratum: Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder—An Animal Model and a Human Study

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good